Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $84.2M | $108M | $184M | $362M | $499M | $703M | $801M | $748M | $940M | $1.01B |
| Revenue growth | — | 27.7% | 70.9% | 97.0% | 37.7% | 40.9% | 14.0% | -6.7% | 25.7% | 7.9% |
| Gross profit | $23.6M | $44.1M | $89.8M | $194M | $261M | $376M | $413M | $368M | $490M | $546M |
| Gross margin | 28.0% | 41.0% | 48.9% | 53.6% | 52.2% | 53.5% | 51.5% | 49.2% | 52.1% | 53.8% |
| Operating income | -$78.1M | -$62.9M | -$44.6M | -$16.7M | -$7.96M | $22.7M | -$92.8M | -$233M | -$99.1M | -$187M |
| Operating margin | -92.6% | -58.5% | -24.3% | -4.6% | -1.6% | 3.2% | -11.6% | -31.2% | -10.5% | -18.5% |
| Net income | -$83.4M | -$73.0M | -$123M | -$24.8M | -$34.4M | $15.6M | -$94.6M | -$223M | -$96.0M | -$205M |
| Net margin | -99.0% | -67.9% | -66.7% | -6.8% | -6.9% | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% |
| EPS (diluted) | -$27.30 | -$12.87 | -$2.55 | -$0.42 | -$0.56 | $0.24 | -$1.47 | -$3.43 | -$1.47 | -$3.04 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$61.2M | -$66.1M | -$8.32M | $41.9M | $24.7M | $111M | $50.5M | -$31.8M | $24.2M | -$9.72M |
| Capital expenditures | $8.93M | $5.72M | $2.99M | $19.5M | $27.4M | $14.2M | $34.1M | $26.8M | $19.2M | $19.9M |
| Free cash flow | -$70.1M | -$71.9M | -$11.3M | $22.4M | -$2.74M | $97.2M | $16.4M | -$58.6M | $4.99M | -$29.7M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $0.00 | $30.0M | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $44.7M | $13.7M | $41.8M | $51.2M | $94.6M | $71.2M | $173M | $58.9M | $69.2M | $90.6M |
| Total assets | $112M | $95.3M | $206M | $326M | $716M | $905M | $1.05B | $953M | $968M | $881M |
| Total liabilities | $118M | $124M | $75.0M | $131M | $350M | $472M | $613M | $639M | $705M | $726M |
| Long-term debt | $81.1M | $82.7M | — | — | — | — | — | $285M | $308M | $310M |
| Shareholders' equity | -$5.93M | -$29.1M | $131M | $195M | $366M | $433M | $440M | $314M | $263M | $155M |
| Retained earnings | -$405M | -$478M | -$600M | -$625M | -$659M | -$635M | -$729M | -$952M | -$1.05B | -$1.25B |
| Shares (wtd avg diluted) | 3.11M | 10.1M | 57.6M | 58.5M | 61.0M | 64.3M | 64.1M | 65.0M | 65.5M | 67.3M |
Every figure is extracted from TANDEM DIABETES CARE INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.